Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics of INCB123667 When Administered Orally to Healthy Adult Participants
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT06909162
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Solid TumorsAdvanced Solid TumorsMetastatic Solid Tumors
- Interventions
- Drug: INCB177054
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 322
- Registration Number
- NCT06873789
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Panorama City, California, United States
🇺🇸University of Florida Health Shands Hospital, Gainesville, Florida, United States
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 600
- Registration Number
- NCT06855498
- Locations
- 🇪🇸
Investigative Site ES018, Valencia, Spain
🇺🇸Investigative Site US086, Birmingham, Alabama, United States
🇺🇸Investigative Site US098, Montgomery, Alabama, United States
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT06843408
- Locations
- 🇨🇳
Peking University People'S Hospital, Beijing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
🇨🇳The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital), Chongqing, China
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT06832618
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Saguaro Dermatology, Phoenix, Arizona, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Drug: INCA034176Drug: Best Available Therapy (BAT)
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT06821542
- Locations
- 🇪🇸
Universitat de Valencia - Hospital Universitari I Politecnic La Fe de Valencia, Valencia, Spain
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
🇦🇹Medical University of Graz, Graz, Austria
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 308
- Registration Number
- NCT06818812
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institue At Healthone, Denver, Colorado, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06804811
Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT06775327
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06713590
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States